Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 7/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110062 | 0.91 | PIM1 (0.40) | CYP11B1CYP11B2PIM1CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL5112800 | 0.90 | PIM1 (0.39) | CYP11B1CYP11B2PIM1CHRNB4CHRNA3 | |
| SCHEMBL5116744 | 0.89 | PIM1 (0.42) | CYP11B1CYP11B2PIM1CHRNB4CHRNA3 | |
| SCHEMBL5120729 | 0.86 | PIM1 (0.41) | CYP11B1CYP11B2PIM1CHRNB4CHRNA3 | |
| SCHEMBL5115668 | 0.86 | CHRNB4 (0.42) | CYP11B2CHRNB4CHRNA3KCNH2CHRNB2 | |
| SCHEMBL5114036 | 0.85 | NR3C1 (0.38) | CYP11B1CYP11B2CHRNB4CHRNA3 | |
| SCHEMBL5121830 | 0.84 | CHRNA1 (0.43) | CYP11B1CYP11B2PIM1CHRNB4CHRNA3 | |
| SCHEMBL5115247 | 0.84 | CYP11B1 (0.45) | CYP11B1CYP11B2CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL5123104 | 0.83 | CHRNB4 (0.52) | CYP11B1CYP11B2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5108370 | 0.82 | CHRNB4 (0.56) | CYP11B1CYP11B2CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC | 2004-06-03 | — | — | US | claimed |
| US-7442694-B2 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC (US) | 2008-10-28 | — | — | US | disclosed |
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | DBH, CHRNA6, DDT | CYP11B1 273/4885CYP11B2 403/4885PIM1 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.